S-1/A: Farlong Holding Corp. Files S-1/A for IPO, Faces Going Concern Doubt

Farlong Holding Corporation filed an S-1/A registration statement for its initial public offering of 4,000,000 shares at an estimated $4.00 per share, seeking to list on Nasdaq under the symbol AFA, despite significant financial challenges.

Summary

• Farlong Holding Corporation is pursuing an Initial Public Offering (IPO) of 4,000,000 shares of common stock at an estimated price of $4.00 per share, aiming to list on the Nasdaq Capital Market under the symbol AFA.
• The company expects to receive net proceeds of approximately $14.5 million from the IPO, or $16.6 million if the underwriters' over-allotment option is fully exercised.
• Proceeds are intended for general corporate purposes, including working capital, R&D, marketing and operational expenses, infrastructure upgrades, and international expansion.
• Farlong reported a net loss of $2,555,522 for the fiscal year ended September 30, 2025, an increase from $1,955,962 in the prior fiscal year.
• The accumulated deficit reached $6,639,708 as of September 30, 2025, with negative operating cash flow of $2,250,279 for the same fiscal year, leading management to express substantial doubt about the company's ability to continue as a going concern.
• Total revenue decreased by 5.19% to $725,806 in fiscal year 2025, primarily due to a strategic decision to streamline product lines by discontinuing non-proprietary products.
• Revenue from the BioPrecision formulation product line, launched in July 2024, increased by 82.30% to $323,171 in fiscal year 2025.
• The DirecTCM platform, launched in May 2025, had approximately 30,000 pre-registered healthcare providers but only 80 active providers as of September 30, 2025, generating immaterial subscription revenue of $1,391 and no direct order revenue in FY2025.
• Cornerstone investors, ACA Care Management, LLC and Epiphron Capital (Hong Kong) Limited, have indicated interest in purchasing up to $2 million and $3 million, respectively, in shares in this offering.

Sentiment

Score: 3

Explanation: The company is pursuing an IPO to raise capital, which is a positive step for growth initiatives like R&D and market expansion. However, the filing explicitly states 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative cash flows. Revenue declined, and while BioPrecision sales grew, overall financial performance is weak. The low active user rate on the DirecTCM platform and expired patents are also concerns, indicating significant underlying risks.

Positives

• The IPO aims to raise significant capital (approximately $14.5 million to $16.6 million) to fund critical growth initiatives including R&D, marketing, infrastructure upgrades, and international expansion.
• The BioPrecision formulation product line demonstrated strong growth, with revenue increasing by 82.30% to $323,171 in fiscal year 2025, validating the company's focus on proprietary, science-backed supplements.
• The DirecTCM platform has attracted a large base of 30,000 pre-registered healthcare providers, indicating significant potential for future engagement and market penetration.
• The company is science-driven, combining traditional herbal knowledge with modern scientific techniques, and is actively pursuing self-affirmed GRAS status for principal botanical ingredients.
• Ongoing preclinical research studies with City of Hope are evaluating the potential health benefits of key botanical ingredients like White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts.
• Completed research studies on Notoginseng, InnerPure, and Breviscapine have shown beneficial effects on cardiovascular health, digestive support, and neuroprotection, with results published on EurekaSelect.
• The company benefits from an established brand (Longstar, founded in 1999) and an experienced management team, including CFO Chiwen Claire Wang, with strong financial expertise.
• Diversified distribution channels, including the DirecTCM platform, major e-commerce sites (Amazon, TikTok, Walmart.com), B2B wholesale, and OEM white-label services, enhance market reach.
• A strategic logistics network with three warehouses across the U.S. (California, Texas, New Jersey) supports rapid, next-day delivery to most regions.

Negatives

• The company has significant accumulated deficits of $6,639,708 as of September 30, 2025, and has experienced recurring net losses ($2,555,522 in FY2025) and negative cash flows from operating activities since 2022, raising substantial doubt about its ability to continue as a going concern.
• Overall revenue decreased by 5.19% in fiscal year 2025, primarily due to the strategic decision to phase out older, non-proprietary products, indicating a contraction in the existing business segments.
• The DirecTCM platform, despite having 30,000 pre-registered healthcare providers, only had 80 active users (0.27%) as of September 30, 2025, and generated immaterial subscription revenue ($1,391) and no direct order revenue in FY2025, suggesting limited current commercialization success.
• Gross margin decreased to 60.31% in fiscal year 2025 from 61.32% in 2024, partly attributed to the BioPrecision formulation product line carrying a relatively lower gross margin of 30.48% as a market entry strategy.
• Selling expenses increased significantly by 182.43% to $450,626 in fiscal year 2025, contributing to the increased net loss.
• Research and development expenses increased from nil in fiscal year 2024 to $106,375 in fiscal year 2025, further impacting profitability.
• Increased interest expense of approximately $0.2 million in fiscal year 2025 was due to additional loans acquired from a related party.
• The company is highly reliant on a small number of customers and vendors; for example, one customer accounted for 21% of FY2025 revenue, and five vendors accounted for 44%, 18%, 15%, 11%, and 10% of total purchases, respectively, in FY2025.
• Approximately 17% of revenue in FY2025 was derived from sales on Amazon and another 17% from TikTok, exposing the company to platform policy changes and potential restrictions.
• Clinical study results to date have not demonstrated statistical significance, which may diminish consumer confidence and limit the effectiveness of marketing claims.
• Material weaknesses were identified in internal control over financial reporting, including a lack of formal risk assessment policies and IT-related deficiencies.
• All U.S. process patents (Patent No. 6,084,080 and 6,500,468) have expired, meaning the company no longer relies on statutory patent protection for these methods.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses from operations and negative cash flows.
• Additional capital will be needed to support operations and expansion, which may not be available on commercially acceptable terms, if at all, potentially leading to dilution for existing stockholders or business curtailment.
• Operating results may vary considerably in the future, making it challenging to forecast performance and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm the business and damage its reputation.
• A significant amount of revenue and purchases are concentrated with a small number of customers and vendors, making the company vulnerable to the loss of any material relationship.
• Customer demand is difficult to forecast accurately, which may lead to an inability to match planning and spending decisions to demand.
• Reliance on Amazon and TikTok platforms for a significant portion of revenue exposes the company to platform policy changes, restrictions, or account suspensions.
• Increases in ingredient costs, long lead times, supply shortages, and changes could disrupt the supply chain and negatively impact financial results.
• The company may allocate limited resources to less profitable products or services, missing greater commercial potential elsewhere.
• Risk of inventory spoliation due to products having definitive shelf-lives, potentially leading to write-offs and significant charges.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect the business.
• Future needs for licenses for third-party technology may be unavailable or offered on commercially unreasonable terms.
• High costs and uncertainty of litigation may prevent the company from effectively enforcing its intellectual property rights against third parties.
• Struggles to partner with others for technological advancements and new products and services could hinder competitiveness.
• Use of open-source software could subject proprietary software to general release, hinder product sales, and expose the company to potential litigation.
• Exposure to risks associated with credit card and other online payment chargebacks and fraud.
• Risks associated with the return policy and warranty if actual returns or warranty claims exceed estimates.
• Clinical studies present inherent risks, and results to date have not demonstrated statistical significance, potentially impacting marketing effectiveness and consumer confidence.
• Dependence on brands (Dr. Herbal Well, Best Doctor Formula) means any failure to maintain, protect, or enhance them could materially and adversely affect the business.
• Reliance on third-party contract manufacturers located in China makes the company highly vulnerable to U.S. tariffs, trade disputes, and other disruptions related to U.S.-China trade relations.
• Intense competition in the herbal supplement industry from existing and new entrants with greater resources could decrease net revenue.
• Global economic conditions, including inflation, recession, and changes to fiscal/monetary policy, could materially and adversely affect the company's business.
• The company is subject to numerous laws and regulations applicable to the herbal supplement industry, and violations could lead to fines, recalls, or operational restrictions.
• Changes in FDA and other regulatory agency policies, or disagreements over product classifications, could delay or increase the costs of offering products.
• Marketing activities for products are subject to strict governmental regulation, which may limit the ability to market or promote products.
• Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection could result in significant liability and harm reputation.
• The company may be subject to allegations, harassment, or other detrimental conduct by third parties, which could harm its reputation and cause loss of market share.
• No public market for common stock prior to this offering, and the market price may be volatile or decline regardless of operating performance.
• New investors will experience immediate and substantial dilution in the net tangible book value of common stock purchased.
• Material weaknesses in internal control over financial reporting have been identified, which could lead to inaccurate financial reporting or fraud.
• The company will incur substantial increased costs as a result of being a public company.
• If the company cannot continue to satisfy Nasdaq listing requirements, its securities may be delisted.
• Management has broad discretion to determine how to use the funds raised in the offering, which may not enhance results or stock price.
• As a controlled company, Farlong could elect to rely on exemptions from certain Nasdaq corporate governance requirements, potentially reducing protections for public stockholders.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to the relatively small public offering and high insider ownership.
• The existence of authorized but unissued preferred stock, which can be designated by the board without stockholder approval, could cause substantial dilution or have anti-takeover effects.
• Anti-takeover provisions in corporate documents and Nevada law might discourage, delay, or prevent a change in control or management.
• The sale of a significant number of shares by large stockholders after lock-up expiration may cause the market price of common stock to drop significantly.

Future Outlook

The company intends to use the net proceeds from the IPO to fund general corporate purposes, including working capital, R&D, marketing and operational expenses, infrastructure upgrades, and international expansion. R&D efforts will focus on refining new products, including self-affirmed GRAS dossiers for two additional extracts, and funding pilot production of next-generation BioPrecision products. Marketing plans include hiring eight field sales representatives and launching three educational roadshows within 15 months. Infrastructure upgrades for the DirecTCM platform are planned over 24 months, including hiring software engineers and increasing cloud capacity. International expansion to Asian and European markets is also a goal, with an expected need for an additional $2 million in capital for a full commercial rollout.

Management Comments

• Simon Cheng, Interim Chief Executive Officer, is responsible for overseeing day-to-day operations, strategic and operational planning, execution of business initiatives, coordinating corporate activities, implementing board directives, and supporting regulatory, governance, and public company obligations.
• Chiwen Claire Wang, Chief Financial Officer, brings a distinguished background in financial management and strategic leadership, overseeing year-end audits, ensuring the accuracy and integrity of financial statements, and managing the auditing process for public companies.
• Management believes the current insurance coverage maintained is in line with the industry.
• Management has determined that recurring losses from operations and negative cash flows from operating activities since 2022 raise substantial doubt about the company's ability to continue as a going concern.

Industry Context

The global dietary supplement market is projected to grow from $74.3 billion in 2024 to $170.1 billion by 2034, at a CAGR of 9.5%, driven by increasing chronic disorders and consumer awareness. The holistic herbal supplement market is also expanding, expected to reach $421 billion by 2032 from $216 billion in 2022, with a CAGR of 6.87%. The U.S. market, a leading supplier in North America, is anticipated to grow at a CAGR of 7.2% from 2024 to 2034. Farlong aims to establish a unique position by combining product quality with personalized wellness solutions, competing with established players like Throne HealthTech, Nestle Health Science, Metagenics, and Fullscript in various segments.

Comparison to Industry Standards

• The company's approach to self-affirming GRAS status for botanical ingredients is a common practice in the dietary supplement industry, where FDA approval is not required or available for such products.
• The preclinical studies sponsored by Farlong are investigator-initiated, dietary supplement studies conducted outside the FDA's investigational-drug framework, which is typical for companies marketing products as dietary supplements rather than drugs.
• The company's insurance coverage is stated to be in line with industry standards, suggesting a baseline level of risk management compared to peers.
• The identified material weaknesses in internal control over financial reporting (lack of formal policies, IT deficiencies) are common challenges for private companies transitioning to public reporting, indicating a need for improvement to meet public company standards.
• The reliance on third-party contract manufacturers in China is a prevalent industry practice for supplement production, but it exposes the company to geopolitical and trade risks that are common for businesses with international supply chains.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed against Longstar on June 20, 2024, by a former employee alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar maintains that all wages were paid in full, and its legal counsel has concluded that the likelihood of liability is remote, with no loss contingency recorded.

Related Party Transactions

• Rent deposit of $19,500 is owed to Longstar Healthpro Manufacturing Inc., which is majority owned by Xinjiang Lixing Investment and Management Co., a former stockholder of Longstar.
• Rent expenses paid to Longstar Healthpro Manufacturing Inc. were $156,650 for FY2025 and $156,000 for FY2024.
• Accounts payable to Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. (where Lihua Zeng, sister of Lipin Zeng, owns 30%) were $60,441 as of September 30, 2025.
• Accounts payable to Kunming Aoqun Bio-Tech Co., Ltd. (where Lihua Zeng serves as director) were $781,668 as of September 30, 2025.
• Accounts payable to Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. (a subsidiary of Yunnan Panlong) were $23,390 as of September 30, 2025.
• Accrued loan interest of $131,933 is owed to Karin Mei Huang as of September 30, 2025.
• Long-term loans from Karin Mei Huang, a stockholder, total $4,600,000 as of September 30, 2025, with annual interest rates of 9.5% and maturity dates ranging from September 2029 to September 2030.
• Products purchased from Kunming Aoqun Bio-Tech Co., Ltd. amounted to $131,148 in FY2025 and $815,172 in FY2024.
• Inventories purchased from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. amounted to $23,390 in FY2025.
• On December 27, 2023, a Share-for-Share Exchange occurred where Karin Mei Huang exchanged 100% of Longstar's equity for 40,000,000 shares of Farlong's common stock.
• On December 31, 2022, Longstar entered into an Asset Transfer Agreement with Xinjiang Lixing, a former majority shareholder under common control of Karin Mei Huang, involving the transfer of real property, common stock, and other assets.

Stakeholder Impact

• **Shareholders**: New investors will experience immediate and substantial dilution of $3.74 per share. Existing shareholders, particularly Karin Mei Huang and her family trusts, will retain significant voting control (90.9% post-IPO). The 'going concern' warning poses a material risk to the value of all shareholder investments.
• **Employees**: The company plans to hire eight field sales representatives, indicating potential job growth. Management changes, including an interim CEO, could create uncertainty. The company has a 401(k) plan and provides health benefits.
• **Customers**: The expansion of the DirecTCM platform and new BioPrecision products could offer enhanced wellness solutions. However, potential supply chain disruptions, product quality issues, or regulatory non-compliance could negatively impact customer trust and product availability.
• **Suppliers**: The company's continued reliance on a few significant suppliers, especially those in China, exposes them to risks from trade disputes and supply chain disruptions, potentially affecting their business relationships.
• **Creditors**: The company has significant related-party debt totaling $4.6 million. The 'going concern' warning indicates potential challenges in meeting financial obligations, which could impact creditors.

Next Steps

• Complete the Initial Public Offering and secure listing on the Nasdaq Capital Market under the symbol AFA.
• Utilize net proceeds from the offering for general corporate purposes, including working capital, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue preclinical research studies with City of Hope for White Button Mushroom, Polygonum Capitatum, and Rodgersia Sambucifolia Hemsl. extracts.
• Refine newly developed products, including pursuing self-affirmed GRAS dossiers for two additional extracts.
• Fund pilot production of next-generation BioPrecision products based on White Button Mushroom extracts (WBM REx).
• Hire eight field sales representatives and launch three educational roadshows within the next 15 months to finance marketing and operational expenses.
• Upgrade the DirecTCM platform, including hiring more internal software engineers and increasing Amazon Web Services and cloud storage capacity within the next 24 months.
• Expand DirecTCM platform service to Asian and European markets, expecting an additional $2 million in capital for a full commercial rollout.
• Identify, evaluate, and recruit a permanent Chief Executive Officer following the resignation of the former CEO.
• Implement a policy prohibiting hedging transactions by employees in the future.
• Form an Audit Committee to review related party transactions and ensure fairness to the company and its stockholders.
• Purchase officers and directors insurance within 30 days after the closing of the offering and maintain it for each officer and director.
• Maintain the listing of the Common Stock on the Nasdaq Capital Market for at least three years from the closing.
• Continue to retain a nationally recognized independent registered public accounting firm for a period of at least three years after the closing.

Key Dates

Recommendation

The filing reveals critical financial distress, including 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative operating cash flows. While the IPO aims to raise capital, the company's revenue is declining, and gross margins are under pressure. The DirecTCM platform, a key growth initiative, shows very low active user engagement. Significant reliance on a few customers and suppliers, coupled with exposure to U.S.-China trade tensions, adds considerable operational risk. The immediate and substantial dilution for new investors, combined with high insider control and expired patents, makes this a highly speculative and risky investment with a strong likelihood of further value erosion.

Keywords

Herbal Supplements, Dietary Supplements, IPO, Nasdaq Listing, Farlong Holding Corporation, BioPrecision, DirecTCM, Traditional Chinese Medicine, Wellness, Healthcare Technology, GRAS, SEC Filing, S-1/A, Nutraceuticals, e-commerce, Supply Chain, R&D, Corporate Governance, Financial Reporting, Going Concern, Risk Factors